Normal view
-
Latest Science News -- ScienceDaily
-
Scientists keep a human alive with a genetically engineered pig liver
Researchers successfully implanted a genetically modified pig liver into a human, proving that such an organ can function for an extended period. The graft supported essential liver processes before complications required its removal. Although the patient ultimately passed away, the experiment demonstrates both the potential and the complexity of xenotransplantation. Experts believe this could reshape the future of organ replacement.
-
(Multiomics OR Omics) AND (Pancreatic)
-
EIF3M as a pan-cancer biomarker: prognostic significance and immune infiltration association
Front Mol Biosci. 2025 Nov 18;12:1697083. doi: 10.3389/fmolb.2025.1697083. eCollection 2025.ABSTRACTBACKGROUND: EIF3M, a core subunit of eukaryotic translation initiation factor 3, plays a pivotal role in protein synthesis by regulating the assembly of the 43S initiation complex. However, its biological functions in cancer remain poorly understood. To further investigate the clinical translational value and underlying mechanisms of EIF3M in tumors, this study conducted comprehensive bioinformati
EIF3M as a pan-cancer biomarker: prognostic significance and immune infiltration association
Front Mol Biosci. 2025 Nov 18;12:1697083. doi: 10.3389/fmolb.2025.1697083. eCollection 2025.
ABSTRACT
BACKGROUND: EIF3M, a core subunit of eukaryotic translation initiation factor 3, plays a pivotal role in protein synthesis by regulating the assembly of the 43S initiation complex. However, its biological functions in cancer remain poorly understood. To further investigate the clinical translational value and underlying mechanisms of EIF3M in tumors, this study conducted comprehensive bioinformatic analysis of EIF3M across various tumor types.
METHODS: We utilized publicly available databases to perform a comprehensive bioinformatics analysis of EIF3M's biological roles in oncogenesis, aiming to elucidate its pan-cancer expression patterns and prognostic significance. Furthermore, we conducted an integrative multi-omics analysis incorporating methylation profiling, co-expressed gene networks, targeted miRNA interactions, and tumor immune microenvironment infiltration to decipher the complex regulatory architecture and biological pathways mediated by EIF3M across cancer types. Finally, we used HCC cell lines for in vitro functional validation, determining how EIF3M expression modulates malignant phenotypic behaviors in hepatocellular carcinoma.
RESULTS: EIF3M was overexpressed in multiple cancers and correlated with advanced tumor stage and poor survival. Its dysregulation was primarily driven by gene amplification and regulated by promoter methylation and miRNAs. EIF3M functioned as a hub in cell cycle and transcriptional networks and was linked to an immunosuppressive microenvironment. In hepatocellular carcinoma models, EIF3M modulated tumor proliferation, migration, and activated oncogenic pathways like Wnt/β-catenin.
CONCLUSION: This study reveals that EIF3M expression correlates with immune infiltration and poor prognosis in multiple cancers. In vitro experiments in hepatocellular carcinoma models demonstrated that EIF3M critically regulates malignant cell behaviors. Collectively, our findings highlight EIF3M's value as a promising pan-cancer biomarker worthy of further investigation for its utility in prognosis prediction and as an indicator of immunotherapeutic response.
PMID:41341921 | PMC:PMC12669982 | DOI:10.3389/fmolb.2025.1697083
-
Journal of Medical Internet Research
-
Detecting Sociodemographic Biases in the Content and Quality of Large Language Model–Generated Nursing Care: Cross-Sectional Simulation Study
Background: Large language models (LLMs) are increasingly applied in healthcare. However, concerns remain that their nursing care recommendations may reflect patients’ sociodemographic attributes rather than clinical needs. Objective: To investigate potential biases in nursing care plans generated by LLMs, we focused on whether outputs differ systematically based on patients’ sociodemographic characteristics and assessed the implications for equitable nursing care. Methods: We utilized a standar
Detecting Sociodemographic Biases in the Content and Quality of Large Language Model–Generated Nursing Care: Cross-Sectional Simulation Study
-
Journal of Medical Internet Research
-
Promoting Responsible DeepSeek Deployment in Health Care: Scoping Review Comparing Grey and White Literature
Background: The rapid deployment of DeepSeek, an open-source large language model has sparked concerns of its impact on patient outcomes and safety. However, little is known about how DeepSeek is used and regulated in these facilities. Objective: This study aimed to 1) systematically review the characteristics of deployed DeepSeek in the top 100 hospitals in China; and 2) compare performances and risks from hospital disclosure with research evidence. Methods: We performed a scoping review of gra
Promoting Responsible DeepSeek Deployment in Health Care: Scoping Review Comparing Grey and White Literature
-
Journal of Medical Internet Research
-
Listening to Patients’ Voices on the Use of AI in Health Care: Cross-Sectional Study
Background: Artificial intelligence (AI) holds great promise in transforming healthcare delivery. However, successful implementation of AI projects in healthcare depends on patients' acceptance and trust. There is only limited empirical research examining public perceptions, particularly on the use of personal health data in AI applications in healthcare. Objective: To examine public knowledge and comfort levels with AI use in healthcare, including use of personal health data with and without co
Listening to Patients’ Voices on the Use of AI in Health Care: Cross-Sectional Study
-
IARC - CSU recent publications
- Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022.
-
TechCrunch
-
Is it time to ‘refound’ your startup?
Sometimes, founding a startup just once isn’t enough.
Is it time to ‘refound’ your startup?
-
InfoQ

-
Podcast: Transforming Life Sciences: AI, Vibe Coding, and Drug Development Acceleration
In this podcast, Shane Hastie, Lead Editor for Culture & Methods, spoke to Satish Kothapalli about the transformative impact of AI and vibe coding in life sciences software development, the acceleration of drug development timelines, and the evolving roles of developers in an AI-augmented environment. By Satish Kothapalli
Podcast: Transforming Life Sciences: AI, Vibe Coding, and Drug Development Acceleration
In this podcast, Shane Hastie, Lead Editor for Culture & Methods, spoke to Satish Kothapalli about the transformative impact of AI and vibe coding in life sciences software development, the acceleration of drug development timelines, and the evolving roles of developers in an AI-augmented environment.
By Satish Kothapalli-
Omics in Hepatocellular
-
EIF3M as a pan-cancer biomarker: prognostic significance and immune infiltration association
Front Mol Biosci. 2025 Nov 18;12:1697083. doi: 10.3389/fmolb.2025.1697083. eCollection 2025.ABSTRACTBACKGROUND: EIF3M, a core subunit of eukaryotic translation initiation factor 3, plays a pivotal role in protein synthesis by regulating the assembly of the 43S initiation complex. However, its biological functions in cancer remain poorly understood. To further investigate the clinical translational value and underlying mechanisms of EIF3M in tumors, this study conducted comprehensive bioinformati
EIF3M as a pan-cancer biomarker: prognostic significance and immune infiltration association
Front Mol Biosci. 2025 Nov 18;12:1697083. doi: 10.3389/fmolb.2025.1697083. eCollection 2025.
ABSTRACT
BACKGROUND: EIF3M, a core subunit of eukaryotic translation initiation factor 3, plays a pivotal role in protein synthesis by regulating the assembly of the 43S initiation complex. However, its biological functions in cancer remain poorly understood. To further investigate the clinical translational value and underlying mechanisms of EIF3M in tumors, this study conducted comprehensive bioinformatic analysis of EIF3M across various tumor types.
METHODS: We utilized publicly available databases to perform a comprehensive bioinformatics analysis of EIF3M's biological roles in oncogenesis, aiming to elucidate its pan-cancer expression patterns and prognostic significance. Furthermore, we conducted an integrative multi-omics analysis incorporating methylation profiling, co-expressed gene networks, targeted miRNA interactions, and tumor immune microenvironment infiltration to decipher the complex regulatory architecture and biological pathways mediated by EIF3M across cancer types. Finally, we used HCC cell lines for in vitro functional validation, determining how EIF3M expression modulates malignant phenotypic behaviors in hepatocellular carcinoma.
RESULTS: EIF3M was overexpressed in multiple cancers and correlated with advanced tumor stage and poor survival. Its dysregulation was primarily driven by gene amplification and regulated by promoter methylation and miRNAs. EIF3M functioned as a hub in cell cycle and transcriptional networks and was linked to an immunosuppressive microenvironment. In hepatocellular carcinoma models, EIF3M modulated tumor proliferation, migration, and activated oncogenic pathways like Wnt/β-catenin.
CONCLUSION: This study reveals that EIF3M expression correlates with immune infiltration and poor prognosis in multiple cancers. In vitro experiments in hepatocellular carcinoma models demonstrated that EIF3M critically regulates malignant cell behaviors. Collectively, our findings highlight EIF3M's value as a promising pan-cancer biomarker worthy of further investigation for its utility in prognosis prediction and as an indicator of immunotherapeutic response.
PMID:41341921 | PMC:PMC12669982 | DOI:10.3389/fmolb.2025.1697083
-
MIT Technology Review

-
Harnessing human-AI collaboration for an AI roadmap that moves beyond pilots
The past year has marked a turning point in the corporate AI conversation. After a period of eager experimentation, organizations are now confronting a more complex reality: While investment in AI has never been higher, the path from pilot to production remains elusive. Three-quarters of enterprises remain stuck in experimentation mode, despite mounting pressure to convert early tests into operational gains. WATCH THE WEBCAST “Most organizations can suffer from what we like to call P
Harnessing human-AI collaboration for an AI roadmap that moves beyond pilots
The past year has marked a turning point in the corporate AI conversation. After a period of eager experimentation, organizations are now confronting a more complex reality: While investment in AI has never been higher, the path from pilot to production remains elusive. Three-quarters of enterprises remain stuck in experimentation mode, despite mounting pressure to convert early tests into operational gains.

“Most organizations can suffer from what we like to call PTSD, or process technology skills and data challenges,” says Shirley Hung, partner at Everest Group. “They have rigid, fragmented workflows that don’t adapt well to change, technology systems that don’t speak to each other, talent that is really immersed in low-value tasks rather than creating high impact. And they are buried in endless streams of information, but no unified fabric to tie it all together.”
The central challenge, then, lies in rethinking how people, processes, and technology work together.
Across industries as different as customer experience and agricultural equipment, the same pattern is emerging: Traditional organizational structures—centralized decision-making, fragmented workflows, data spread across incompatible systems—are proving too rigid to support agentic AI. To unlock value, leaders must rethink how decisions are made, how work is executed, and what humans should uniquely contribute.
“It is very important that humans continue to verify the content. And that is where you’re going to see more energy being put into,” Ryan Peterson, EVP and chief product officer at Concentrix.
Much of the conversation centered on what can be described as the next major unlock: operationalizing human-AI collaboration. Rather than positioning AI as a standalone tool or a “virtual worker,” this approach reframes AI as a system-level capability that augments human judgment, accelerates execution, and reimagines work from end to end. That shift requires organizations to map the value they want to create; design workflows that blend human oversight with AI-driven automation; and build the data, governance, and security foundations that make these systems trustworthy.
“My advice would be to expect some delays because you need to make sure you secure the data,” says Heidi Hough, VP for North America aftermarket at Valmont. “As you think about commercializing or operationalizing any piece of using AI, if you start from ground zero and have governance at the forefront, I think that will help with outcomes.”
Early adopters are already showing what this looks like in practice: starting with low-risk operational use cases, shaping data into tightly scoped enclaves, embedding governance into everyday decision-making, and empowering business leaders, not just technologists, to identify where AI can create measurable impact. The result is a new blueprint for AI maturity grounded in reengineering how modern enterprises operate.
“Optimization is really about doing existing things better, but reimagination is about discovering entirely new things that are worth doing,” says Hung.
This webcast is produced in partnership with Concentrix.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.
-
STAT

-
STAT+: Hengrui, BeOne top new analysis of Chinese drug development
A new report is peeling back the curtain on Chinese pharmaceutical innovation, assessing which companies are best at driving the drug development that’s captured the attention of pharmaceutical executives and investors worldwide. On Sunday, IDEA Pharma and parent company SAI MedPartners released their inaugural China Pharmaceutical Innovation and Invention Index. The report joins a global pharmaceutical ranking that IDEA produces every spring. The rankings were chosen from a list of 50 c
STAT+: Hengrui, BeOne top new analysis of Chinese drug development
A new report is peeling back the curtain on Chinese pharmaceutical innovation, assessing which companies are best at driving the drug development that’s captured the attention of pharmaceutical executives and investors worldwide.
On Sunday, IDEA Pharma and parent company SAI MedPartners released their inaugural China Pharmaceutical Innovation and Invention Index. The report joins a global pharmaceutical ranking that IDEA produces every spring.
The rankings were chosen from a list of 50 companies around China. The report ranks the top companies for invention — namely, which companies are developing new medicines that matter and use novel science — and innovation, which assesses how these companies are developing and launching medicines. Research spending, international patent filings, and drug approvals all factor into a company’s standing.
Continue to STAT+ to read the full story…


© Adobe
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Hydrogel Formulations to Investigate Lung Cancer Mechanism
Thorac Res Pract. 2025 Dec 1;26(Suppl 1):10-11. doi: 10.4274/ThoracResPract.2025.s004.ABSTRACTINTRODUCTION: Lung cancer remains a leading cause of cancer-related deaths worldwide, largely due to late diagnosis and the complexity of the tumor microenvironment (TME).1 A key factor in lung cancer is the extracellular matrix (ECM), a 3D network composed of structural proteins, glycoproteins, proteoglycans, and growth factors that together regulate cell adhesion, proliferation, and signaling. ECM arc
Hydrogel Formulations to Investigate Lung Cancer Mechanism
Thorac Res Pract. 2025 Dec 1;26(Suppl 1):10-11. doi: 10.4274/ThoracResPract.2025.s004.
ABSTRACT
INTRODUCTION: Lung cancer remains a leading cause of cancer-related deaths worldwide, largely due to late diagnosis and the complexity of the tumor microenvironment (TME).1 A key factor in lung cancer is the extracellular matrix (ECM), a 3D network composed of structural proteins, glycoproteins, proteoglycans, and growth factors that together regulate cell adhesion, proliferation, and signaling. ECM architecture and its changes are closely related to cancer mechanisms.2 Thus, physiological models that recapitulate ECM composition and mechanics are essential. 2D cultures fail to replicate the organization and biochemical and mechanical signals of the TME, whereas microfluidic platforms offer dynamic, 3D cell culture systems hydrogel-integrated.3 A broad range of biomaterials (synthetic, semi-synthetic, natural) is used to recapitulate the dynamics of ECM. Natural hydrogels such as collagen, gelatin methacrylate (GelMA), Matrigel, alginate, fibrin, and decellularized ECM (dECM) are widely used due to their inherent bioactivity and ability to support cell adhesion and proliferation.4 Synthetic hydrogels, such as polyethylene glycol (PEG) and polyacrylamide, provide tunable stiffness and control over matrix composition, while semi-synthetic hybrids (e.g., PEG-GelMA, GelMA-dECM) combine biological cues with structural stability (Figure 1).5.
MATERIAL AND METHODS: Cancer cell lines A549 (adenocarcinoma), H1299 (non-small cell lung cancer), and H460 (large cell carcinoma) are frequently used in cancer modelling. Co-culture systems integrate fibroblasts, endothelial cells, and immune cells (e.g., macrophages) to simulate the TME and study cell-matrix-cell interactions. Patient-derived organoids preserve tumor heterogeneity, genetic mutations, and drug response profiles, representing a personalized in vitro cancer model. Tumor spheroids embedded in hydrogels recapitulate diffusion gradients and are used to evaluate drug penetration and metastasis. Further, they can be integrated into microfluidic platforms or well plates. As a next step, it is important to investigate ECM rheology, determine mechanical structure and cytokine expression levels, and further validate cell-matrix interactions.6,7.
RESULTS: These models have shown that tumor cells embedded in hydrogels exhibit enhanced invasive behavior and increased expression of matrix metalloproteinases (enzymes responsible for ECM degradation and remodeling). From a biomechanical perspective, rheological analyses revealed that cancer-associated hydrogels typically exhibit higher storage modulus than healthy matrices, reflecting a stiffer microenvironment and increased collagen levels.8.
CONCLUSION: Collectively, recent findings underscore the central role of the ECM and hydrogel-based systems in modeling lung cancer progression. The development of tissue-specific, mechanically tunable, and microfluidic-integrated hydrogels has transformed in vitro modeling from static 2D monolayers to dynamic, physiologically relevant 3D systems. Increased stiffness is now recognized as a key regulator of cancer cell fate, governing proliferation, EMT, and metastasis through mechanotransduction pathways such as YAP/TAZ and integrin-FAK signaling.9 Despite significant progress, variability in dECM composition and crosslinking chemistry still challenges reproducibility and bioactivity. Moreover, current hydrogel-based models often lack immune cell components and vascular complexity, limiting their ability to fully emulate the native TME. Future efforts should integrate dECM-based hydrogels with organoid and microfluidic systems, supported by multi-omics profiling, to achieve patient-specific and physiologically relevant lung cancer models.
PMID:41340224 | PMC:PMC12673191 | DOI:10.4274/ThoracResPract.2025.s004
-
npj Digital Medicine
-
Mixed methods evaluation of a clinical decision support system to reduce variation in healthcare
npj Digital Medicine, Published online: 06 December 2025; doi:10.1038/s41746-025-02141-9Mixed methods evaluation of a clinical decision support system to reduce variation in healthcare
Mixed methods evaluation of a clinical decision support system to reduce variation in healthcare
npj Digital Medicine, Published online: 06 December 2025; doi:10.1038/s41746-025-02141-9
Mixed methods evaluation of a clinical decision support system to reduce variation in healthcare-
npj Digital Medicine
-
A typology of physician input approaches to using AI chatbots for clinical decision-making
npj Digital Medicine, Published online: 05 December 2025; doi:10.1038/s41746-025-02184-yA typology of physician input approaches to using AI chatbots for clinical decision-making
A typology of physician input approaches to using AI chatbots for clinical decision-making
npj Digital Medicine, Published online: 05 December 2025; doi:10.1038/s41746-025-02184-y
A typology of physician input approaches to using AI chatbots for clinical decision-making-
FDA Press Releases RSS Feed
-
FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies
The U.S. Food and Drug Administration today announced the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, a voluntary pilot designed to promote access to certain digital health devices while safeguarding patient safety.
FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
LOSTdb: a manually curated multi-omics database for lung cancer research
BMC Bioinformatics. 2025 Dec 3;26(1):290. doi: 10.1186/s12859-025-06319-6.ABSTRACTLung cancer is one of the most prevalent malignant tumors with high morbidity and mortality rates worldwide. Extensive multi-omics analyses have revealed significant intratumoral heterogeneity even within the same histopathological subtype. However, a database that systematically integrates multi-omics data for lung cancer research has long been lacking. Here, we developed LOSTdb, a molecular subtype annotation sys
LOSTdb: a manually curated multi-omics database for lung cancer research
BMC Bioinformatics. 2025 Dec 3;26(1):290. doi: 10.1186/s12859-025-06319-6.
ABSTRACT
Lung cancer is one of the most prevalent malignant tumors with high morbidity and mortality rates worldwide. Extensive multi-omics analyses have revealed significant intratumoral heterogeneity even within the same histopathological subtype. However, a database that systematically integrates multi-omics data for lung cancer research has long been lacking. Here, we developed LOSTdb, a molecular subtype annotation system for lung cancer that integrates multi-omics data and metadata. LOSTdb comprises 295 multi-omics datasets, including bulk RNA-seq, genomic, proteomic, methylation, and scRNA-seq data, with over 10,000 manually curated metadata entries. This resource encompasses high-quality clinical specimens, mouse models, and cell lines, totaling 34,393 samples and more than 1.2 million single cells. Each omics sample was annotated with both literature-based classical subtypes and NMF-derived meta-program (MP) subtypes. The platform supports cross-searching of omics and metadata at the gene and dataset levels, offers multiple visualization and analysis methods, and includes five tool modules, enabling functions such as integrated analysis, significance analysis between metadata as well as between genes and metadata, and target prediction for lung cancer molecular subtypes, serving as an essential tool for lung cancer precision medicine. LOSTdb is a user-friendly interactive database freely accessible at http://lostdbcancer.com:8080 .
PMID:41339793 | DOI:10.1186/s12859-025-06319-6
-
cs.AI, q-bio.NC updates on arXiv.org
-
Exploring Syntropic Frameworks in AI Alignment: A Philosophical Investigation
arXiv:2512.03048v1 Announce Type: new Abstract: I argue that AI alignment should be reconceived as architecting syntropic, reasons-responsive agents through process-based, multi-agent, developmental mechanisms rather than encoding fixed human value content. The paper makes three philosophical contributions. First, I articulate the ``specification trap'' argument demonstrating why content-based value specification appears structurally unstable due to the conjunction of the is-ought gap, value pl
Exploring Syntropic Frameworks in AI Alignment: A Philosophical Investigation
-
cs.AI, q-bio.NC updates on arXiv.org
-
Beyond the Black Box: A Cognitive Architecture for Explainable and Aligned AI
arXiv:2512.03072v1 Announce Type: new Abstract: Current AI paradigms, as "architects of experience," face fundamental challenges in explainability and value alignment. This paper introduces "Weight-Calculatism," a novel cognitive architecture grounded in first principles, and demonstrates its potential as a viable pathway toward Artificial General Intelligence (AGI). The architecture deconstructs cognition into indivisible Logical Atoms and two fundamental operations: Pointing and Comparison. D
Beyond the Black Box: A Cognitive Architecture for Explainable and Aligned AI
-
cs.AI, q-bio.NC updates on arXiv.org
-
Privacy Risks and Preservation Methods in Explainable Artificial Intelligence: A Scoping Review
arXiv:2505.02828v3 Announce Type: replace Abstract: Explainable Artificial Intelligence (XAI) has emerged as a pillar of Trustworthy AI and aims to bring transparency in complex models that are opaque by nature. Despite the benefits of incorporating explanations in models, an urgent need is found in addressing the privacy concerns of providing this additional information to end users. In this article, we conduct a scoping review of existing literature to elicit details on the conflict between p
Privacy Risks and Preservation Methods in Explainable Artificial Intelligence: A Scoping Review
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Definition of AGI
arXiv:2510.18212v3 Announce Type: replace Abstract: The lack of a concrete definition for Artificial General Intelligence (AGI) obscures the gap between today's specialized AI and human-level cognition. This paper introduces a quantifiable framework to address this, defining AGI as matching the cognitive versatility and proficiency of a well-educated adult. To operationalize this, we ground our methodology in Cattell-Horn-Carroll theory, the most empirically validated model of human cognition.